BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laudato S, Aparicio A, Giancotti FG. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. Trends Cancer. 2019;5:440-455. [PMID: 31311658 DOI: 10.1016/j.trecan.2019.05.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hassan S, Blick T, Wood J, Thompson EW, Williams ED. Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models. Front Cell Dev Biol 2022;10:858013. [DOI: 10.3389/fcell.2022.858013] [Reference Citation Analysis]
2 Flores M, Goodrich DW. Retinoblastoma Protein Paralogs and Tumor Suppression. Front Genet 2022;13:818719. [DOI: 10.3389/fgene.2022.818719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Zhu S, Du Y, Xu F, Sun W, Xu Z, Wang X, Qian P, Zhang Q, Feng J, Xu Y. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res 2022;41:66. [PMID: 35177112 DOI: 10.1186/s13046-022-02243-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Zhang W, Wang T, Wang Y, Zhu F, Shi H, Zhang J, Wang Z, Qu M, Zhang H, Wang T, Qian Y, Yang J, Gao X, Li J. Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis. Transl Oncol 2021;16:101311. [PMID: 34902740 DOI: 10.1016/j.tranon.2021.101311] [Reference Citation Analysis]
5 Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Impellizzieri D, Di Rito L, Zoni E, Mosole S, Elia AR, Rinaldi A, Pereira Mestre R, D'Antonio E, Ferrari M, Stoffel F, Jermini F, Gillessen S, Bubendorf L, Schraml P, Calcinotto A, Corey E, Moch H, Spahn M, Thalmann G, Kruithof-de Julio M, Rubin MA, Theurillat JP. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun 2021;12:7033. [PMID: 34857732 DOI: 10.1038/s41467-021-26840-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2021. [PMID: 34773527 DOI: 10.1007/s10147-021-02074-9] [Reference Citation Analysis]
7 Luo Y, Vlaeminck-Guillem V, Baron S, Dallel S, Zhang CX, Le Romancer M. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin. J Exp Clin Cancer Res 2021;40:270. [PMID: 34446068 DOI: 10.1186/s13046-021-02058-7] [Reference Citation Analysis]
8 Li W, Shen MM. Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models. Semin Cancer Biol 2021:S1044-579X(21)00186-3. [PMID: 34147640 DOI: 10.1016/j.semcancer.2021.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wei W, Li QG, Long X, Hu GH, He HJ, Huang YB, Yi XL. Sarcomatoid carcinoma of the prostate with bladder invasion shortly after androgen deprivation: Two case reports. World J Clin Cases 2021; 9(7): 1668-1675 [PMID: 33728311 DOI: 10.12998/wjcc.v9.i7.1668] [Reference Citation Analysis]
10 Singh D, Bocci F, Kulkarni P, Jolly MK. Coupled Feedback Loops Involving PAGE4, EMT and Notch Signaling Can Give Rise to Non-genetic Heterogeneity in Prostate Cancer Cells. Entropy (Basel) 2021;23:288. [PMID: 33652914 DOI: 10.3390/e23030288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Hass R, von der Ohe J, Ungefroren H. The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes. Cancers (Basel) 2020;12:E3674. [PMID: 33297508 DOI: 10.3390/cancers12123674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
12 Wang Y, Gao W, Li Y, Chow ST, Xie W, Zhang X, Zhou J, Chan FL. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer. Mol Aspects Med 2021;78:100921. [PMID: 33121737 DOI: 10.1016/j.mam.2020.100921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Federer-Gsponer JR, Müller DC, Zellweger T, Eggimann M, Marston K, Ruiz C, Seifert HH, Rentsch CA, Bubendorf L, Le Magnen C. Patterns of stemness-associated markers in the development of castration-resistant prostate cancer. Prostate 2020;80:1108-17. [PMID: 32628318 DOI: 10.1002/pros.24039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ripoll GV, Pifano M, Garona J, Alonso DF. Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Front Oncol 2019;9:1490. [PMID: 31998646 DOI: 10.3389/fonc.2019.01490] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Civenni G, Carbone GM, Catapano CV. Mitochondrial fission and stemness in prostate cancer. Aging (Albany NY) 2019;11:8036-8. [PMID: 31575828 DOI: 10.18632/aging.102339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]